High-Cost Benefit of Chlorambucil in Frequently Relapsing Nephrosis

Claire Kleinknecht, Pierre Guesry, Gérard Lenoir, Michel Broyer, Warren E. Grupe, Sudesh P Makker, Julie R. Ingelfinger

Research output: Contribution to journalLetter

22 Scopus citations

Abstract

To the Editor: Grupe et al. (N Engl J Med 295:746, 1976) demonstrated the beneficial effect of chlorambucil in frequently relapsing nephrosis. Despite their excellent results and the good tolerance of the drug, the authors gave strong advice against the wide use of chlorambucil because of its potential toxicity. Our data afford further evidence of both the efficacy and the toxicity of the drug. Sixty-two children with frequent relapsing nephrosis who received chlorambucil were followed for more than one year after withdrawal of the drug. Initial dosage was 0.2 mg per kilogram per day in 45 patients and 0.1.

Original languageEnglish (US)
Pages (from-to)48-49
Number of pages2
JournalNew England Journal of Medicine
Volume296
Issue number1
DOIs
StatePublished - Jan 6 1977
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'High-Cost Benefit of Chlorambucil in Frequently Relapsing Nephrosis'. Together they form a unique fingerprint.

  • Cite this

    Kleinknecht, C., Guesry, P., Lenoir, G., Broyer, M., Grupe, W. E., Makker, S. P., & Ingelfinger, J. R. (1977). High-Cost Benefit of Chlorambucil in Frequently Relapsing Nephrosis. New England Journal of Medicine, 296(1), 48-49. https://doi.org/10.1056/NEJM197701062960115